You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review

Optimal long-term osteoporosis drug treatment (ODT) is uncertain. The purpose of this systematic review is to summarize the effects of long-term ODT and ODT discontinuation and holidays.

CONCLUSION: Long-term alendronate and zoledronic acid therapies reduce fracture risk in women with osteoporosis. Long-term bisphosphonate treatment may increase risk for rare adverse events, and continuing treatment beyond 3 to 5 years may reduce risk for vertebral fractures. Long-term hormone therapy reduces hip fracture risks but has serious harms.

About Annals Articles

Many articles published in the Annals of Internal Medicine (annals.org) offer CME credit and MOC points, earned by reading the articles and subsequently completing a multiple-choice quiz to demonstrate knowledge. Note that CME and MOC availability typically expires 3 years after article publication, but quizzes remain available to allow learners to test their knowledge.


Details

CME/MOC:

Up to 1 AMA PRA Category 1 Credits ™ and MOC Points
Expires April 23, 2022   active

Cost:

Free to Members

Format:

Journal Articles

Product:

Annals Articles